Geron (GERN) Operating Expenses (2010 - 2026)
Geron's (GERN) quarterly Operating Expenses came in at $70.0 million in Q2 2026, up 13.8% year-over-year from $61.5 million in Q2 2025, and up 35.41% quarter-over-quarter from $51.7 million in Q1 2026.
Analysis
Geron (GERN) Operating Expenses (2010 - 2026) Analysis & Trends
Geron has disclosed Operating Expenses across 17 years of filings, most recently posting $70.0 million for Q2 2026.
- In Q2 2026, Operating Expenses rose 13.8% year-over-year to $70.0 million; the TTM figure through Jun 2026 stood at $256.3 million (up 5.98% YoY), while the FY2025 annual figure was $252.5 million, up 0.69% from the prior year.
- Operating Expenses came in at $70.0 million for Q2 2026 at Geron, up from $51.7 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $73.6 million in Q4 2025 to a low of $28.0 million in Q2 2022.
- Average Operating Expenses over 5 years is $53.2 million, with a median of $55.3 million recorded in 2023.
- Year-over-year, Operating Expenses soared 85.32% in 2023 and retreated 12.43% in 2025.
- Over 5 years, Operating Expenses stood at $42.1 million in 2022, then increased by 29.15% to $54.3 million in 2023, then rose by 24.44% to $67.6 million in 2024, then climbed by 8.83% to $73.6 million in 2025, then declined by 4.87% to $70.0 million in 2026.
- Per Business Quant data, the three most recent Operating Expenses figures were $70.0 million in Q2 2026, $51.7 million in Q1 2026, and $73.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 6.54 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 18.20 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 2.09 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 3.00 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.05 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 960.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 2.60 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 367.83 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 69.98 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 69.98 Mn |
| Mar 31, 2026 | 51.68 Mn |
| Dec 31, 2025 | 73.56 Mn |
| Sep 30, 2025 | 61.11 Mn |
| Jun 30, 2025 | 61.49 Mn |
| Mar 31, 2025 | 56.31 Mn |
| Dec 31, 2024 | 67.59 Mn |
| Sep 30, 2024 | 56.49 Mn |
| Jun 30, 2024 | 70.22 Mn |
| Mar 31, 2024 | 56.44 Mn |
| Dec 31, 2023 | 54.31 Mn |
| Sep 30, 2023 | 47.78 Mn |
| Jun 30, 2023 | 51.98 Mn |
| Mar 31, 2023 | 40.11 Mn |
| Dec 31, 2022 | 42.05 Mn |
| Sep 30, 2022 | 40.25 Mn |
| Jun 30, 2022 | 28.05 Mn |
| Mar 31, 2022 | 28.80 Mn |
| Dec 31, 2021 | 32.02 Mn |
| Sep 30, 2021 | 25.78 Mn |